{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:59:37Z","timestamp":1790769577085,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In recent years, the practice of routinely obtaining day 14 bone marrow biopsies during AML intensive induction therapy has been scrutinized. While current guidelines recommend obtaining mid-induction biopsies to gauge early response to treatment and guide potential changes in future management, concerns have been raised that these biopsies may not be as prognostically accurate as hoped and subsequently may result in additional and unwarranted chemotherapy toxicity in select patients. In this review, our goal is to summarize the most recent evidence surrounding day 14 bone marrow biopsies that have been published and clarify the utility of this currently recommended practice. Here, we review major developments in mid-induction biopsy in AML, along with ongoing and future planned studies in this area, outlining the limitations of available data and our future goals.<\/jats:p>","DOI":"10.3390\/cancers17050900","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:02:13Z","timestamp":1741240933000},"page":"900","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Revisiting the Role of Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"17","author":[{"given":"Omer","family":"Jamy","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Bourne","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2300-4499","authenticated-orcid":false,"given":"Todd William","family":"Mudd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9754-5036","authenticated-orcid":false,"given":"Haley","family":"Thigpen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"ref_1","unstructured":"Vakiti, A., Reynolds, S.B., and Mewawalla, P. (2025). Acute Myeloid Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_3","unstructured":"SEER (2024, September 21). SEER Cancer Statistics Review, 1975\u20132016, Available online: https:\/\/seer.cancer.gov\/csr\/1975_2016\/index.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2015.07.646","article-title":"How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia","volume":"15","author":"Hahn","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_8","first-page":"6287","article-title":"Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine","volume":"35","author":"Wiedower","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107467","DOI":"10.1016\/j.leukres.2024.107467","article-title":"Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia","volume":"139","author":"Bourne","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1080\/10428194.2024.2373324","article-title":"Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia","volume":"65","author":"Diebold","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2019.09.613","article-title":"Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results","volume":"20","author":"Jamy","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/ajh.24818","article-title":"Day 14 bone marrow examination in the management of acute myeloid leukemia","volume":"92","author":"Terry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_18","first-page":"1285","article-title":"Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia","volume":"85","author":"Liso","year":"2000","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.21133","article-title":"Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia","volume":"83","author":"Hussein","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2013.091819","article-title":"Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: Long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group","volume":"99","author":"Bertoli","year":"2014","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajh.24627","article-title":"Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience","volume":"92","author":"Griffin","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.clml.2020.02.012","article-title":"Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort","volume":"20","author":"England","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/crst.crst_90_21","article-title":"The utility of day 14 bone marrow response assessment in patients undergoing acute myeloid leukemia induction: A single institution retrospective experience","volume":"4","author":"Nair","year":"2021","journal-title":"Cancer Res. Stat. Treat."},{"key":"ref_25","first-page":"3865","article-title":"Prognostic Value of Day 14 Bone Marrow Biopsy (d14BM) in Acute Myeloid Leukemia (AML)","volume":"130","author":"Lemos","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3324\/haematol.12825","article-title":"Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia","volume":"93","author":"Yanada","year":"2008","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2012.09.016","article-title":"Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia","volume":"37","author":"Morris","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood.V124.21.1004.1004","article-title":"Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?","volume":"124","author":"Deutsch","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/leu.2014.268","article-title":"Value of routine \u2018day 14\u2019 marrow exam in newly diagnosed AML","volume":"29","author":"Yezefski","year":"2015","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.leukres.2016.04.013","article-title":"A new model to predict remission status in AML patients based on day 14 bone marrow biopsy","volume":"46","author":"Norkin","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_31","first-page":"421","article-title":"Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases","volume":"19","author":"Alsaleh","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1309\/FY0UMAMM91VPMR2W","article-title":"Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry","volume":"129","author":"Gillis","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Li, W. (2022). Flow Cytometry in the Diagnosis of Leukemias. Leukemia, Exon Publications.","DOI":"10.36255\/exon-publications-leukemia-flow-cytometry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1309\/AJCPW10YBRMWSWYE","article-title":"Diagnostic Yield of Bone Marrow and Peripheral Blood FISH Panel Testing in Clinically Suspected Myelodysplastic Syndromes and\/or Acute Myeloid Leukemia: A Prospective Analysis of 433 Cases","volume":"135","author":"Coleman","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1158\/1078-0432.CCR-23-1674","article-title":"Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia","volume":"30","author":"Qin","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100023","DOI":"10.1016\/j.amolm.2023.100023","article-title":"Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target","volume":"2","author":"Quattrocchi","year":"2023","journal-title":"Asp. Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Jansko-Gadermeir, B., Leisch, M., Gassner, F.J., Zaborsky, N., Dillinger, T., Hutter, S., Risch, A., Melchardt, T., Egle, A., and Drost, M. (2023). Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group. Cancers, 15.","DOI":"10.3390\/cancers15082305"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ajcp\/68.4.440","article-title":"Diagnosis of acute leukemia. Variability of morphologic criteria","volume":"68","author":"Tan","year":"1977","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.leukres.2018.06.003","article-title":"Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study","volume":"74","author":"Matsuda","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"Kramer","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2016.48","article-title":"Prediction of CR following a second course of \u20187+3\u2019 in patients with newly diagnosed acute myeloid leukemia not in CR after a first course","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1182\/blood.V126.23.4974.4974","article-title":"The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival","volume":"126","author":"Ollila","year":"2015","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.24207","article-title":"Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the \u201c3\u2009+\u20097\u201d induction regimen for acute myeloid leukemia","volume":"90","author":"Ofran","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2021.280027","article-title":"Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning","volume":"108","author":"Eckardt","year":"2023","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/leu.2008.296","article-title":"Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: A GOELAMS study","volume":"23","author":"Lacombe","year":"2009","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3760\/cma.j.issn.0366-6999.20132107","article-title":"The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia","volume":"127","author":"Gao","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1002\/cncr.27494","article-title":"Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia","volume":"118","author":"Arellano","year":"2012","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41409-023-01977-7","article-title":"Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia","volume":"58","author":"Jamy","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101238","DOI":"10.1016\/j.blre.2024.101238","article-title":"Ven the dose matters: Venetoclax dosing in the frontline treatment of AML","volume":"68","author":"Sastow","year":"2024","journal-title":"Blood Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","article-title":"Phase I\/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML","volume":"142","author":"Yilmaz","year":"2023","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/900\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:59Z","timestamp":1760028479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050900"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050900","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}